A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-γ treatment
-
- Paul J. Mosca
- From the Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC; and Immunex Inc, Seattle, WA.
-
- Amy C. Hobeika
- From the Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC; and Immunex Inc, Seattle, WA.
-
- Timothy M. Clay
- From the Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC; and Immunex Inc, Seattle, WA.
-
- Smita K. Nair
- From the Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC; and Immunex Inc, Seattle, WA.
-
- Elaine K. Thomas
- From the Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC; and Immunex Inc, Seattle, WA.
-
- Michael A. Morse
- From the Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC; and Immunex Inc, Seattle, WA.
-
- H. Kim Lyerly
- From the Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC; and Immunex Inc, Seattle, WA.
書誌事項
- 公開日
- 2000-11-15
- DOI
-
- 10.1182/blood.v96.10.3499
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Dendritic cells (DCs) may arise from multiple lineages and progress through a series of intermediate stages until fully mature, at which time they are capable of optimal antigen presentation and T-cell activation. High cell surface expression of CD83 is presumed to correlate with full maturation of DCs, and a number of agents have been shown to increase CD83 expression on DCs. We hypothesized that interleukin 12 (IL-12) expression would be a more accurate marker of functionally mature DCs capable of activating antigen-specific T cells. We used combinations of signaling through CD40, using CD40 ligand trimer (CD40L), and interferon gamma to demonstrate that CD83 expression is necessary but not sufficient for optimal production of IL-12 by DCs. Phenotypically mature DCs could be induced to produce high levels of IL-12 p70 only when provided 2 simultaneous stimulatory signals. By intracellular cytokine detection, we determined that only a subset of cells that express high levels of CD80 and CD83 generate large amounts of IL-12. DCs matured with both signals are superior to DCs stimulated with the individual agents in activating antigen-specific T cell in vitro. These findings have important implications regarding the identification, characterization, and clinical application of functionally mature DCs.</jats:p>
収録刊行物
-
- Blood
-
Blood 96 (10), 3499-3504, 2000-11-15
American Society of Hematology